Amphion Innovations plc

Directorate Change

London and New York, 20 April 2018 - Amphion Innovations plc (AIM: AMP), the developer of medical, life science, and technology businesses, announces that Miroslaw Izienicki and Richard Mansell-Jones have resigned as Non-executive Director and Chairman respectively and will leave the Board with immediate effect. 

The Company has begun the process of seeking suitable candidates to fill these positions and will update shareholders accordingly.

Richard C.E. Morgan, Chief Executive Officer of Amphion said: “I would like to thank Miroslaw and Richard for their service to Amphion over the years.  We wish them both well for the future. 

“Our team at Amphion remains confident in the futures of Motif Bio and Polarean Imaging, both now publically listed companies, as well as the future potential of FireStar Software.  We believe that as our companies’ progress, Amphion’s shareholders will benefit in turn and we look forward to building on that base with new investment opportunities in the life-sciences sector.”

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 ("MAR").

---

For further information please contact

Amphion Innovations
Charlie Morgan
+1 212 210 6224

Panmure Gordon Limited (Nominated Adviser and Corporate Broker)
Freddy Crossley / Ryan McCarthy (Corporate Finance)
Charlie Leigh-Pemberton (Corporate Broking)
+44 (0)20 7886 2500

Northland Capital Partners Limited (Joint Corporate Broker)
Patrick Claridge / David Hignell (Corporate Finance)
John Howes (Corporate Broking)
+44 (0)20 3861 6600

Walbrook PR
Anna Dunphy / Paul McManus
+44 (0)20 7933 8780

About Amphion Innovations plc
Amphion Innovations is a developer of medical, life science and technology businesses.

We use our extensive experience in company building to invest and build shareholder value in high growth companies in the US and UK. Amphion has significant shareholding in a small number of Partner Companies developing proven technologies targeting substantial commercial marketplaces. The Amphion model has been refined to optimise the commercialisation of patents and other intellectual property within the Partner Companies.